Cheng Zhao-Zhao, Gao Feng, Lv Xin-Yi, Wang Qiong, Wu Yan, Sun Bao-Liang, Shen Yong
Cheeloo College of Medicine, Shandong University, Jinan, China.
Department of Neurology, Institute on Aging and Brain Disorders, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
J Alzheimers Dis. 2023;91(2):795-804. doi: 10.3233/JAD-220872.
Cerebral small vessel disease (CSVD), which comprises the typical features of white matter hyperintensity (WMH) and Vichor-Robin spaces (VRSs) in the brain, is one of the leading causes of aging-related cognitive decline and, ultimately, contributes to the occurrence of dementia, including Alzheimer's disease (AD).
To investigate whether CSVD imaging markers modify the pathological processes of AD and whether these markers improve AD diagnosis.
208 participants were enrolled in the China Aging and Neurodegenerative Initiative (CANDI). Fluid AD biomarkers were detected using a single-molecule array, and cerebral small vessel dysfunction was determined using magnetic resonance imaging.
WMH contributed to AD pathology only within the NC and MCI groups (CDR ≤0.5), whereas VRSs had no effect on AD pathology. The associations between AD biomarkers and cognitive mental status were consistent with the presence of CSVD pathology. That is, within individuals without CSVD pathology, the MMSE scores were correlated with AD fluid biomarkers, except for plasma Aβ42 and Aβ40. Increased plasma p-Tau levels were associated with worse cognitive performance in individuals with WMH (β= -0.465, p = 0.0016) or VRSs (β= -0.352, p = 0.0257) pathology. Plasma AD biomarkers combined with CSVD markers showed high accuracy in diagnosing dementia.
Findings from this cross-sectional cohort study support the notion that CSVD is a risk factor for dementia and highlights that vascular pathology can promote AD biomarker levels, especially in the early course of the disease. Moreover, our results suggest that adding a vascular category to the ATN framework improves the diagnostic accuracy of AD.
脑小血管病(CSVD)包括脑白质高信号(WMH)和血管周围间隙(VRSs)等典型特征,是衰老相关认知衰退的主要原因之一,最终会导致包括阿尔茨海默病(AD)在内的痴呆症的发生。
研究CSVD成像标志物是否会改变AD的病理过程,以及这些标志物是否能改善AD的诊断。
208名参与者被纳入中国衰老与神经退行性疾病倡议(CANDI)研究。使用单分子阵列检测脑脊液AD生物标志物,并通过磁共振成像确定脑小血管功能障碍。
仅在NC和MCI组(CDR≤0.5)中,WMH对AD病理有影响,而VRSs对AD病理无影响。AD生物标志物与认知精神状态之间的关联与CSVD病理的存在一致。也就是说,在没有CSVD病理的个体中,MMSE评分与AD脑脊液生物标志物相关,但血浆Aβ42和Aβ40除外。在有WMH(β=-0.465,p=0.0016)或VRSs(β=-0.352,p=0.0257)病理的个体中,血浆p-Tau水平升高与较差的认知表现相关。血浆AD生物标志物与CSVD标志物联合使用在痴呆诊断中显示出高准确性。
这项横断面队列研究的结果支持CSVD是痴呆症危险因素的观点,并强调血管病理可促进AD生物标志物水平升高,尤其是在疾病早期。此外,我们的结果表明,在ATN框架中增加血管类别可提高AD的诊断准确性。